Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas

1. Durvalumab improves survival in gastric cancer patients. 2. MATTERHORN trial involved 948 patients with resectable tumors. 3. Significant overall survival benefits across PD-L1 expression levels. 4. Higher event-free survival observed with durvalumab plus FLOT. 5. Pathologic complete response rates higher with the combination therapy. 6. Study results support changing treatment standards.